SLC5A2 and hydrops fetalis: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been presented as novel pharmacological therapy for patients with heart failure (HF), showing reductions in hospitalization for HF and mortality in multiple randomized controlled trials [1–5].